CHIAMBARETTA F, GARRAFFO R, ELENA PP, POULIQUEN P, DELVAL L, RIGAL D, DUBRAY C, GOLDSCHMIDT P, TABBARA K, COCHEREAU I. Tear concentrations of azithromycin following topical administration of a single dose of azithromycin 0.5%, 1.0%, and 1.5% eyedrops (T1225) in healthy volunteers. Eur. J. Ophthalmol. 2008;18(1) : 13-20. » to see the abstract

CLERGET-CHOSSAT N (a), CAILLAUD T (a), and ELENA PP (a). La recherche biomédicale en France : ce qui a changé depuis 2004. J. Fr. Ophtalmol. 2008;31 : 80-86.
(a) IRIS PHARMA, Nice, France

CROS BOIDEVEZI M (a), STEVE L (a), JOUVENCEL R (a),CLIROPHTHA (b). Trend of prescription of silicon hydrogel lens by ophthalomologists and lens assessment by patients. 29th IEEE EMBS Annual International Conference 2007; Lyon - France.
(a) CIBA Vision France, Paris, France - (b) CLIROPHTHA, Nice, France

DUBOIS P, ZEMMOURI J, ROULAND JF, ELENA PP, LOPES R, PUECH P. A new method for intra ocular pressure in vivo measurement: first clinical trials. 29th IEEE EMBS Annual International Conference 2007; Lyon - France.

ELENA PP(a), The role of the CROs in the ophthalmological drug development in Europe. ISOPT meeting 2006; Berlin - Germany. » to see the abstract
(a) CLIROPHTHA, Nice, France

GARCHER C, PASSEMARD M, LAFONTAINE PO, VIAU S, JOFFRE C, ELENA PP, POULIQUEN P, BAUDOUIN C and BRON AM. Improvement of dry eye symptoms with polyunsaturated fatty acids. ARVO meeting 2006; Fort Lauderdale, FL - USA.Invest. Ophthalmol. Vis. Sci. 2006;47: ARVO e-abstract No. 236.

GARCHER C, PASSEMARD M, VIAU S, JOFFRE C, LAFONTAINE PO, ELENA PP, POULIQUEN P, BAUDOUIN C and BRON AM. Amélioration de la symptomatologie chez des patients atteints de sécheresse oculaire et traités oralement par des acides gras polyinsaturés. Improvement of dry eye symptoms with polyunsaturated fatty acids. SFO meeting 2006; Paris - France. Oral communication No. 220.

DELFOUR-MALECAZE M(a), STEVE L(b), CLIROPHTHA(c). Enquête prospective, nationale, multicentrique auprès de 345 patients anciens et nouveaux porteurs sur la santé oculaire, la performance visuelle et la satisfaction des lentilles 0₂ OPTIX TORIC. Réflexions Ophtalmol. 2006;95 : 50-53
(a) Toulouse, France (b) CIBA Vision France, Paris, France - (c) CLIROPHTHA, Nice, France

CREUZOT C, PASSEMARD M, VIAU S, JOFFRE C, POULIQUEN P, ELENA PP, BRON A and BRIGNOLE F. Improvement of dry eye symptoms with polyunsaturated fatty acids.J. Fr. Ophtalmol. 2006;29(8) : 868-73. » to see the abstract

CROS BOIDEVEZI M(a), STEVE L(a), JOUVENCEL R(a), CLIROPHTHA(b). Trend of prescription of silicon hydrogel lens by ophthalomologists and lens assessment by patients. 36th ECLSO Congress 2006; Dubrovnik - Czech Republic. Abstract No. 9. » to see the abstract
(a) CIBA Vision France, Paris, France - (b) CLIROPHTHA, Nice, France

MONTARD M. Etude comparative des implants Alcon asphériques (SN60WF) versus standards (SN60AT). Safir meeting 2006. Paris - France (collaboration).

GARCHER C (a), PASSEMARD M (a), LAFONTAINE PO (a), VIAU S (b), JOFFRE C (b), ELENA PP(c), POULIQUEN P(d), BAUDOUIN C(e) and BRON AM(a). Improvement of dry eye symptoms with polyunsaturated fatty acids. EVER meeting 2006; Vilamoura - Portugal, free paper No. 3155 and poster No. 335. » to see the abstract
(a) Hopital General, Dijon, France - (b) INRA - Eye and Nutrition Unit, Dijon, France (c) CLIROPHTHA, Nice, France (d) Laboratoires THEA, Clermont-Ferrand, France - (e) CHNO XV-XX, Paris, France

GARCHER C, PASSEMARD M, LAFONTAINE PO, VIAU S, JOFFRE C, ELENA PP, POULIQUEN P, BAUDOUIN C and BRON AM. Improvement of dry eye symptoms with polyunsaturated fatty acids. Acta Ophthalmologica Scandinavica. 2006;84 Supplement 239 : 135.

MALET F, CLIROPHTHA. Regard® : une enquête sur la tolérance et le confort oculaire d'une solution d'entretien pour lentilles de contact sans conservateur. Réflexions Ophtalmol. 2005;84 : 62-65.

RENARD P(a), KOVALSKI JL(b), COCHEREAU I(c), JAULERRY S(d), WILLIAMSON W(e), ELENA PP(f), LABLACHE COMBIER M(g), ALLAIRE C(g) AND SIOU-MERMET R(g). Comparison of carteolol plasmatic levels after repeated instillations of long-acting and regular formulations of carteolol 2% in glaucoma patients. Graefe's Arch. Clin. and Exp. Ophthalmol. 2005;243 : 1221-1227. » to see the abstract
(a) Institut Vernes, Paris, France - (b) HIA Clermont Tonnerre, Brest, France - (c) CHRU, Angers, France - (d) CH Tarbes Vic Bigorre, Tarbes, France - (e) CH François Mitterrand, Pau, France - (f) Iris Pharma-Clirophtha, La Gaude, France - (g) Bausch & Lomb, Paris, France

BRON A, VELASQUE L, REBICA H, POULIQUEN P, ELENA PP, AND ROULAND JF. Comparison of once-daily nonpreserved timolol and timolol maleate gel-forming solution associated with latanoprost. J. Fr. Ophtalmol. 2004;27(9 Pt 1) : 971-7. » to see the abstract

ROULAND JF,MOREL-MANDRINO P, DE GREGORIO F, BAROZZI C AND FEDELI E. Non-inferiority, in the intra-ocular pressure (IOP)-lowering effect, of a new eye-drops formulation of 0.5% timolol (Timolast™) instilled once-daily versus 0.5% Timoptol®, instilled twice-daily, for 4 months in ocular hypertensive or glaucomatous patients. ARVO meeting 2004; Fort Lauderdale, FL – USA.Invest. Ophthalmol. Vis. Sci. 2004;45 : ARVO e-abstract No. 2080.

ALLAIRE CM, RENARD P, KOVALSKI J, COCHEREAU I, JAULERRY S, WILLIAMSON W, ELENA PP AND LABLACHE-COMBIER M. Comparison of carteolol plasmatic levels after repeated instillations of long acting and regular formulations of carteolol 2% in glaucomatous patients. ARVO meeting 2004; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 2004;45 : ARVO e-abstract No. 957.

GOLDSCHMIDT P, ELENA PP, BALDWIN H, DELVAL L AND COLIN J. Efficacy and safety of diclofenac 0.1% ABAK® versus preserved diclofenac® 0.1% eye drops in controlling post-cataract surgery inflammation. ARVO meeting 2004; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 2004;45 : ARVO e-abstract No. 294.

ROULAND JF(a), MOREL-MANDRINO P(b), ELENA PP(b), DE GREGORIO F(c), BAROZZI C(c), FEDELI E(c) AND FERREIRA VD(c). Ocular hypotensive effect of a new “once-daily” eye-dops formulation of 0.5% timolol (Timolast™) in comparison to Timoptol® 0.5% administered twice-daily. ISOPT meeting 2004; Monte-Carlo – Monaco.
(a) Hôpital Huriez, Lille, France - (b) CLIROPHTHA, Nice, France - (c) TUBILUX Pharma SpA, Roma, Italy

ROULAND JF(a), MOREL-MANDRINO P(b), ELENA PP(b), POLZER H(c) and SUNDER RAJ P(d). Timolol 0.1% Gel (Nyogel 0.1%®) Once Daily versus Conventional Timolol 0.5% Solution Twice Daily: A Comparison of Efficacy and Safety.Ophthalmologica 2002;216 : 449-454. » to see the abstract
(a) Hôpital Huriez, Lille, France - (b) CLIROPHTHA, Nice, France - (c) MEDproject Pharma, Sauerlach, Germany - (d) Novartis Ophthalmics, Farnborough, UK

ROULAND JF(a), MOREL-MANDRINO P(b), ELENA PP(b) and POLZER H(c). A Novel Once-a-Day Timolol 0.1% Gel Formulation has an equivalent IOP-lowering efficacy to timolol 0.5% solution. IGS meeting 2001; Prague - Czech Republic. » to see the abstract
(a) Hôpital Huriez, Lille, France - (b) CLIROPHTHA, Nice, France - (c) MEDproject Pharma, Sauerlach, Germany

SECHOY O (a), TISSIE G (a), SEBASTIAN C (a), MAURIN F (a), DRIOT JY (a) AND TRINQUANT C (a). A new long acting ophthalmic formulation of carteolol containing alginic acid. Int. J. Pharm. 2000;207 : 109-116. (collaboration) » to see the abstract
(a) Laboratorie CHAUVIN, Montpellier, France

ELENA PP, ROULAND JF, MOREL-MANDRINO P AND POLZER H. Therapeutic equivalence of a timolol 0.1% hydrogel (T-Gel 0.1%) QD and aqueous timolol 0.5% BID in reducting the IOP of glaucomatous patients. ARVO meeting 2000; Fort Lauderdale, FL – USA.Invest. Ophthalmol. Vis. Sci. 2000;41 : S281, abstract No. 2477.

NORDMANN JP, ELENA PP AND VILAIN C. Intraocular pressure effects of topical rilmenidine in ocular hypertensive animals and in healthy volunteers and glaucoma subjects. ISECOPP meeting 1997 Munich – Germany, p. 12.

NORDMANN JP, ROULAND JF, ELENA PP AND KAPOK B. Efficacy and local ocular tolerance of Rescula eye drops in glaucoma patients. ISECOPP meeting 1997 Munich – Germany, p. 27.

NORDMANN JP, ELENA PP, MOREL-MANDRINO P, CASTAGNE I AND VILAIN C. Rilmenidine : safety and efficacy on intraocular pressure in healthy volunteers and glaucoma patients. ARVO meeting 1997; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 1997;38 : S559, abstract No. 2600.

POULIQUEN P(a), ELENA PP(b), MALECAZE F(c), LUYCKX J(a), LANOUE A(a) AND GOLDSCHMIDT P(d). Assessment of the safety and local pharmacokinetics of 0.15 % gel of ganciclovir (Virgan®) in healthy volunteers. ARVO meeting 1996; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 1996;37 : S313, abstract No. 1431.
(a) Laboratoires THEA, Clermont-Ferrand, France - (b) CLIROPHTHA, Nice, France - (c) Hôpital Purpan, Toulouse, France - (d) Centre Hospitalier Universitaire de la Pitié-Salpêtrière, Paris, France

NORDMANN JP, PERCICOT CL, ELENA PP AND MATHIS GA. Intraocular pressure effects of topical renin inhibitor CGP 38560 in normal and ocular hypertensive animals and in healthy volunteers and glaucoma subjects. ISECOPP meeting 1995; Geneva – Switzerland, p. 35.

DENIS P, NORDMANN JP, ELENA PP, JAILLON P, MATHIS G AND SARAUX H. One drop study to evaluate safety and efficacy of SR43845, a renin inhibitor, in healthy volunteers. ARVO meeting 1995, Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 1995;36 : S734, abstract No. 3388.

NORDMANN JP, DENIS P, ELENA PP, MATHIS GA, SCHNARR KD, TETZLOFF W AND KERKMANN T. Evaluation of safety and efficacy of CGP38560, a renin inhibitor, in healthy volunteers and glaucoma subjects.ARVO meeting 1995, Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 1995;36 : S719, abstract No. 3317.

DENIS P (a), NORDMANN JP (a), ELENA PP (b), SARAUX H (a) AND LAPALUS P(c). Central nervous system control of intraocular pressure. Fundam. Clin. Pharmacol. (France) 1994;8 : 230-237. » to see the abstract
(a) Hôpital Saint-Antoine, dep. ophthalmology, Paris, France - (b) IRIS PHARMA, Nice, France - (c) School medicine, dep. pharmacology, Nice, France